Aurora Kinases as Targets in Drug-Resistant Neuroblastoma Cells
Figure 3
Role of p53 signalling in response to aurora kinase inhibition.
A) tozasertib-induced p53 and p21 expression as indicated by Western blot after 24 h of incubation; B) tozasertib- and alisertib-induced expression of p53 target genes in UKF-NB-3 cells in which p53 was depleted using a lentiviral vector encoding shRNA directed against p53 (UKF-NB-3p53shRNA) or in UKF-NB-3 cells transduced with a control vector encoding non-targeting scramble shRNA (UKF-NB-3scr) as indicated by qPCR after 24 h. Expression levels are presented as fold change relative to non-treated controls. * P<0.05 relative to non-treated control; C) tozasertib and alisertib concentrations that reduce UKF-NB-3, UKF-NB-3scr, and UKF-NB-3p53shRNA viability by 50% (IC50). * P<0.05 relative to UKF-NB-3 cells.